Biltmore Family Office’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.51M | Buy |
4,906
+971
| +25% | +$984K | 0.63% | 32 |
|
|
2025
Q4 | $4.23M | Buy |
3,935
+673
| +21% | +$644K | 0.58% | 36 |
|
|
2025
Q3 | $2.49M | Buy |
3,262
+65
| +2% | +$48.4K | 0.35% | 56 |
|
|
2025
Q2 | $2.49M | Sell |
3,197
-70
| -2% | -$54.4K | 0.42% | 47 |
|
|
2025
Q1 | $2.7M | Hold |
3,267
| – | – | 0.46% | 42 |
|
|
2024
Q4 | $2.52M | Sell |
3,267
-26
| -0.8% | -$21.5K | 0.42% | 44 |
|
|
2024
Q3 | $2.92M | Buy |
3,293
+288
| +10% | +$259K | 0.5% | 38 |
|
|
2024
Q2 | $2.72M | Buy |
3,005
+81
| +3% | +$64.8K | 0.5% | 41 |
|
|
2024
Q1 | $2.27M | Hold |
2,924
| – | – | 0.45% | 43 |
|
|
2023
Q4 | $1.7M | Hold |
2,924
| – | – | 0.35% | 48 |
|
|
2023
Q3 | $1.57M | Sell |
2,924
-78
| -3% | -$40.2K | 0.36% | 52 |
|
|
2023
Q2 | $1.41M | Sell |
3,002
-69
| -2% | -$28.9K | 0.3% | 52 |
|
|
2023
Q1 | $1.05M | Buy |
3,071
+52
| +2% | +$17.5K | 0.22% | 69 |
|
|
2022
Q4 | $1.1M | Sell |
3,019
-92
| -3% | -$32.6K | 0.23% | 65 |
|
|
2022
Q3 | $1.01M | Buy |
3,111
+4
| +0.1% | +$1.27K | 0.23% | 60 |
|
|
2022
Q2 | $1.01M | Sell |
3,107
-2,373
| -43% | -$712K | 0.25% | 68 |
|
|
2022
Q1 | $1.57M | Hold |
5,480
| – | – | 0.34% | 49 |
|
|
2021
Q4 | $1.51M | Buy |
5,480
+1,550
| +39% | +$393K | 0.29% | 56 |
|
|
2021
Q3 | $908K | Hold |
3,930
| – | – | 0.22% | 73 |
|
|
2021
Q2 | $902K | Hold |
3,930
| – | – | 0.26% | 66 |
|
|
2021
Q1 | $734K | Hold |
3,930
| – | – | 0.23% | 69 |
|
|
2020
Q4 | $664K | Sell |
3,930
-26
| -0.7% | -$3.88K | 0.2% | 72 |
|
|
2020
Q3 | $586K | Hold |
3,956
| – | – | 0.33% | 68 |
|
|
2020
Q2 | $649K | Hold |
3,956
| – | – | 0.39% | 65 |
|
|
2020
Q1 | $549K | Sell |
3,956
-33
| -0.8% | -$4.53K | 0.36% | 73 |
|
|
2019
Q4 | $524K | Buy |
3,989
+193
| +5% | +$22.4K | 0.21% | 90 |
|
|
2019
Q3 | $425K | Hold |
3,796
| – | – | 0.18% | 106 |
|
|
2019
Q2 | $421K | Hold |
3,796
| – | – | 0.23% | 87 |
|
|
2019
Q1 | $493K | Hold |
3,796
| – | – | 0.25% | 87 |
|
|
2018
Q4 | $439K | Sell |
3,796
-1,400
| -27% | -$156K | 0.25% | 92 |
|
|
2018
Q3 | $558K | Hold |
5,196
| – | – | 0.27% | 87 |
|
|
2018
Q2 | $443K | Hold |
5,196
| – | – | 0.22% | 92 |
|
|
2018
Q1 | $402K | Hold |
5,196
| – | – | 0.18% | 118 |
|
|
2017
Q4 | $439K | Buy |
+5,196
| New | +$442K | 0.2% | 102 |
|
Other funds holding LLY
VCM
VPM
Biltmore Family Office's LLY Position: Q1 2026 in Review
Biltmore Family Office increased its Eli Lilly (LLY) stake by 25% in Q1 2026, buying an estimated $984K and bringing the position to 4,906 shares worth $4.51M. The position accounts for 0.63% of the portfolio, ranked #32.
Biltmore Family Office first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Biltmore Family Office held 4,906 shares of Eli Lilly worth $4.51M as of Q1 2026.
- Biltmore Family Office bought 971 Eli Lilly shares in Q1 2026, an estimated $984K.
- Eli Lilly made up 0.63% of Biltmore Family Office's portfolio in Q1 2026, its #32 holding.
- Biltmore Family Office first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
- 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Biltmore Family Office's 13F filing for Q1 2026, filed 11 May 2026.